Cargando…

Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy

PURPOSE: To assess the optimal time of intravitreal conbercept (IVC) treatment prior to pars plana vitrectomy (PPV) in patients with severe proliferative diabetic retinopathy (PDR). METHOD: This study was exploratory in nature. Forty-eight consecutive patients (48 eyes) with PDR were divided into fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhikun, Di, Yu, Ye, Junjie, Yu, Weihong, Guo, Zijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254397/
https://www.ncbi.nlm.nih.gov/pubmed/37305048
http://dx.doi.org/10.3389/fendo.2023.1171628
_version_ 1785056633090473984
author Yang, Zhikun
Di, Yu
Ye, Junjie
Yu, Weihong
Guo, Zijian
author_facet Yang, Zhikun
Di, Yu
Ye, Junjie
Yu, Weihong
Guo, Zijian
author_sort Yang, Zhikun
collection PubMed
description PURPOSE: To assess the optimal time of intravitreal conbercept (IVC) treatment prior to pars plana vitrectomy (PPV) in patients with severe proliferative diabetic retinopathy (PDR). METHOD: This study was exploratory in nature. Forty-eight consecutive patients (48 eyes) with PDR were divided into four groups according to different IVC times (0.5 mg/0.05 mL) before PPV: group A (3 days), group B (7 days), group C (14 days), and group D (non-IVC). Intraoperative and postoperative effectiveness were assessed, and vitreous VEGF concentrations were detected. RESULT: For intraoperative effectiveness, groups A and D had a higher incidence of intraoperative bleeding than groups B and C (P = 0.041). Furthermore, groups A-C required less surgical time than group D (P < 0.05). For postoperative effectiveness, group B had a significantly higher proportion of visual acuity that improved or remained unchanged than group D (P = 0.014), and groups A-C had lower proportions of postoperative bleeding than group D. The vitreous VEGF concentration of group B (67.04 ± 47.24 pg/mL) was significantly lower than that of group D (178.29 ± 110.50 pg/mL) (P = 0.005). CONCLUSION: IVC treatment that was administered 7 days preoperatively was associated with better effectiveness and a lower vitreous VEGF concentration than its administration at other time points.
format Online
Article
Text
id pubmed-10254397
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102543972023-06-10 Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy Yang, Zhikun Di, Yu Ye, Junjie Yu, Weihong Guo, Zijian Front Endocrinol (Lausanne) Endocrinology PURPOSE: To assess the optimal time of intravitreal conbercept (IVC) treatment prior to pars plana vitrectomy (PPV) in patients with severe proliferative diabetic retinopathy (PDR). METHOD: This study was exploratory in nature. Forty-eight consecutive patients (48 eyes) with PDR were divided into four groups according to different IVC times (0.5 mg/0.05 mL) before PPV: group A (3 days), group B (7 days), group C (14 days), and group D (non-IVC). Intraoperative and postoperative effectiveness were assessed, and vitreous VEGF concentrations were detected. RESULT: For intraoperative effectiveness, groups A and D had a higher incidence of intraoperative bleeding than groups B and C (P = 0.041). Furthermore, groups A-C required less surgical time than group D (P < 0.05). For postoperative effectiveness, group B had a significantly higher proportion of visual acuity that improved or remained unchanged than group D (P = 0.014), and groups A-C had lower proportions of postoperative bleeding than group D. The vitreous VEGF concentration of group B (67.04 ± 47.24 pg/mL) was significantly lower than that of group D (178.29 ± 110.50 pg/mL) (P = 0.005). CONCLUSION: IVC treatment that was administered 7 days preoperatively was associated with better effectiveness and a lower vitreous VEGF concentration than its administration at other time points. Frontiers Media S.A. 2023-05-26 /pmc/articles/PMC10254397/ /pubmed/37305048 http://dx.doi.org/10.3389/fendo.2023.1171628 Text en Copyright © 2023 Yang, Di, Ye, Yu and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Yang, Zhikun
Di, Yu
Ye, Junjie
Yu, Weihong
Guo, Zijian
Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
title Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
title_full Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
title_fullStr Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
title_full_unstemmed Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
title_short Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
title_sort comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254397/
https://www.ncbi.nlm.nih.gov/pubmed/37305048
http://dx.doi.org/10.3389/fendo.2023.1171628
work_keys_str_mv AT yangzhikun comparisonoftheadjuvanteffectofconberceptintravitrealinjectionatdifferenttimesbeforevitrectomyforproliferativediabeticretinopathy
AT diyu comparisonoftheadjuvanteffectofconberceptintravitrealinjectionatdifferenttimesbeforevitrectomyforproliferativediabeticretinopathy
AT yejunjie comparisonoftheadjuvanteffectofconberceptintravitrealinjectionatdifferenttimesbeforevitrectomyforproliferativediabeticretinopathy
AT yuweihong comparisonoftheadjuvanteffectofconberceptintravitrealinjectionatdifferenttimesbeforevitrectomyforproliferativediabeticretinopathy
AT guozijian comparisonoftheadjuvanteffectofconberceptintravitrealinjectionatdifferenttimesbeforevitrectomyforproliferativediabeticretinopathy